Hairy cell leukemia is commonly treated with which regimen?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Study for the Step 3 UWSA Exam with our challenging quiz. Prepare with detailed explanations for each question, ensuring you're well-equipped for success. Enhance your understanding and boost your exam confidence!

Multiple Choice

Hairy cell leukemia is commonly treated with which regimen?

Explanation:
Hairy cell leukemia responds exceptionally well to purine analog chemotherapy. The standard frontline regimen is cladribine, also known as 2CDA (2-chlorodeoxyadenosine), given as a short IV course. It achieves complete remissions in most patients and often provides durable remissions. Other drugs like methotrexate or cyclophosphamide aren’t the typical first-line choices for this disease, and rituximab is more commonly used in relapsed or refractory cases. So the commonly used regimen is cladribine (2CDA).

Hairy cell leukemia responds exceptionally well to purine analog chemotherapy. The standard frontline regimen is cladribine, also known as 2CDA (2-chlorodeoxyadenosine), given as a short IV course. It achieves complete remissions in most patients and often provides durable remissions. Other drugs like methotrexate or cyclophosphamide aren’t the typical first-line choices for this disease, and rituximab is more commonly used in relapsed or refractory cases. So the commonly used regimen is cladribine (2CDA).

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy